Cereno Scientific completes SEK 100 million directed share issue and secures SEK 350 million loan financing

"MAQS Advokatbyrå advised Cereno Scientific on a SEK 100m directed B‑share issue and a loan facility securing up to SEK 350m. The board also resolved to issue warrants that could raise an additional SEK 215m, bringing potential total financing to SEK 665m to fund milestones through Q4 2027."

MAQS Advokatbyrå advised biotechnology company Cereno Scientific in connection with a directed issue of new B‑shares and a loan financing agreement. The transaction comprises a directed share issue of new B‑shares totalling SEK 100 million and a loan financing agreement securing financing of up to SEK 350 million. In addition, the Board of Directors has resolved to issue warrants which, if fully exercised, may provide the company with an additional SEK 215 million. Upon full exercise of both warrants and convertibles, the total potential financing amounts to SEK 665 million. The purpose of the financing is to secure the financial runway for Cereno Scientific to reach its set milestones in the fourth quarter of 2027. Cereno Scientific is an innovative biotechnology company pioneering treatments for rare cardiovascular and pulmonary diseases and is listed on Nasdaq First North. MAQS Advokatbyrå represented Cereno Scientific with a team composed by: Eric Ehrencrona, Fredrik Brusberg, Rebecka Malm and Albin Davidsson Sirestål.

Cereno Scientific completes SEK 100 million directed share issue and secures SEK 350 million loan financing

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads